Alnylam Pharmaceuticals, Inc.
As of Oct 22, 2026, Alnylam Pharmaceuticals is in Stage 4, the downtrend phase, now in week 36 (since Feb 11, 2026). It closed at $227.28, 52.8% below its 52-week high and below its 200-day average, which is falling.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ALNY early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ALNY among Biotechnology351st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …351 | ALNY | Stage 4 · wk 36 | 23 | −7.8% |
Alnylam Pharmaceuticals: quick answers
What stage is Alnylam Pharmaceuticals in?
As of Oct 22, 2026, Alnylam Pharmaceuticals (ALNY) is in Stage 4, the downtrend phase. It entered Stage 4 on Feb 11, 2026 and is in week 36. What the four stages mean
Is Alnylam Pharmaceuticals in an uptrend?
No. Alnylam Pharmaceuticals is in a Stage 4 downtrend. It trades 21.9% below its 200-day average, which is falling.
How far is Alnylam Pharmaceuticals from its 52-week high?
Alnylam Pharmaceuticals closed at $227.28 on Oct 22, 2026, 52.8% below its 52-week high of $481.59. Its 52-week low is $205.48.
How has Alnylam Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Alnylam Pharmaceuticals is down 52.1% over the past year and down 43.2% so far in 2026.
Which sector and industry is Alnylam Pharmaceuticals in?
Alnylam Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.